


1. (Previously Presented) A compound of formula (I) or a salt, N-oxide, hydrate or solvate thereof, for inhibition of kinase activity:



wherein

Ring A is an optionally substituted carbocyclic or heterocyclic radical,

Alk represents an optionally substituted divalent C₁-C₆ alkylene radical;

n is 0 or 1 ;

Q represents a radical of formula -(Alk¹)_p-(X)_r-(Alk²)_s-Z wherein in any compatible combination

Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring,

Alk¹ and Alk² are optionally substituted divalent C₁-C₆ alkylene radicals which may contain a -O-, -S- or -NR^A-link, wherein R^A is hydrogen or C₁-C₆ alkyl,

X represents -O-, -S-, -(C=O)-, -(C=S)-, -SO₂-, -SO-, -C(=O)O-, -OC(=O)-, -C(=O)NR^A-,
 .NR^AC(=O)-, -C(=S)NR^A-, -NR^AC(=S)-, -SO₂NR^A-, -NR^ASO₂-, -OC(=O)NR^A-, -
 NRAC(=O)O-, or -NR^A- wherein R^A is hydrogen or C₁-C₆ alkyl, and

p, r and s are independently 0 or 1,

R_1 represents a radical $-(Alk^3)_a-(Y)_b-(Alk^4)_d-B$ wherein a, b and d are independently 0 or 1,

Alk^3 and Alk^4 are optionally substituted divalent C_1-C_3 alkylene radicals,

Y represents a monocyclic divalent carbocyclic or heterocyclic radical having from 5 to 8 ring atoms, -O-, -S-, or -NR^A- wherein R^A is hydrogen or C_1-C_6 alkyl,

B represents hydrogen or halo, or an optionally substituted monocyclic carbocyclic or heterocyclic ring having from 5 to 8 ring atoms, or in the case where Y is -NR^A- and b is 1, then R^A and the radical $-(Alk^4)_d-B$ taken together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring,

R represents hydrogen, halo, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_1-C_6 alkylthio, phenyl, benzyl, cycloalkyl with 3 to 6 ring atoms, or a monocyclic heterocyclic group having 5 or 6 ring atoms.

2. (Previously Presented) The compound as claimed in claim 1 wherein ring A is an optionally substituted monocyclic aryl or heteroaryl radical.

3. (Previously Presented) The compound as claimed in claim 2 wherein ring A is phenyl, naphthyl, 2-, 3- and 4-pyridyl, 5-pyrimidinyl, 2- and 3-thienyl, 2- and 3-furyl, piperazinyl, pyrrolidinyl, or thiazolinyl.

4. (Previously Presented) The compound as claimed in claim 1 wherein ring A is phenyl.

5. (Previously Presented) The compound as claimed in claim 1 wherein ring A is unsubstituted or

substituted by methyl, ethyl, methylenedioxy, ethylenedioxy, methoxy, ethoxy, methylthio, ethylthio, hydroxy, hydroxymethyl, hydroxyethyl, mercapto, mercaptomethyl, mercaptoethyl, amino, mono- or di-methylamino, mono- or di-ethylamino, fluoro, chloro, bromo, cyano, N-morpholino, N-piperidinyl, or N-piperazinyl, the latter being optionally C₁-C₆ alkyl- or benzyl-substituted on the free ring nitrogen, dimethylaminosulfonyl, phenylsulfonyl or phenoxy.

6. (Previously Presented) The compound as claimed in claim 1 wherein Q is hydrogen and the ring A is 4-(dimethylaminosulfonyl)-phenyl, 4-(phenylsulfonyl)-phenyl, 4-(phenoxy)-phenyl, 3-chloro-4-(dimethylaminosulfonyl)-phenyl, 3-chloro-4-(phenylsulfonyl)-phenyl, 3-chloro-4-(phenoxy)-phenyl, 3-methoxy-4-(dimethylaminosulfonyl)-phenyl, 3-methoxy-4-(phenylsulfonyl)-phenyl, or 3-methoxy-4-(phenoxy)-phenyl.

7. (Previously Presented) The compound as claimed in claim 1 wherein n is 1 and Alk is CH₂-, -CH₂CH₂-, -CH₂CH(CH₃)-, -CH₂CH₂CH₂-, -CH=CH-, -CH₂CH=CH-, -CH₂CH=CHCH₂-, -CH=CHCH=CH-, -C≡C-, -CH₂C≡C-, or -CH₂C≡CCH₂-.

8. (Previously Presented) The compound as claimed in claim 1 wherein n is 1 and Alk is -CH₂-.

9. (Previously Presented) The compound as claimed in claim 1 wherein n is 0.

10. (Previously Presented) The compound as claimed in claim 1 wherein each of p, r and s is 0, and Z is hydrogen.

11. (Previously Presented) The compound as claimed in claim 1 wherein p, r and s are each 0, and Z is an optionally substituted monocyclic carbocyclic or heterocyclic ring.

12. (Previously Presented) The compound as claimed in claim 11 wherein Z is an optionally substituted phenyl, cyclopentyl, cyclohexyl, pyridyl, morpholino, piperidinyl, or piperazyl ring.

13. (Previously Presented) The compound as claimed in claim 1 wherein one or more of p, r and s is 1, and Z is hydrogen or an optionally substituted monocyclic carbocyclic or heterocyclic ring.

14. (Previously Presented) The compound as claimed in claim 13 wherein p, s, or both are each 1 and r is 0

15. (Previously Presented) The compound as claimed in claim 13 wherein each of p, r, and s is 1.

16. (Previously Presented) The compound as claimed in claim 13 wherein p and s are each 0 and r is 1.

17. (Previously Presented) The compound as claimed in claim 16 wherein X is $-\text{SO}_2-$, $-\text{O}-$, a sulfonamide radical $-\text{NR}^{\text{A}}\text{SO}_2-$ or a carboxamide radical $-\text{NR}^{\text{A}}\text{C}(=\text{O})-$ with the N atom linked to the ring A.

18. (Previously Presented) The compound as claimed in claim 13 wherein p is 0, r is 1, s is 1 or 0, and X is a sulfonamide radical $-\text{NR}^{\text{A}}\text{SO}_2-$ or a carboxamide radical $-\text{NR}^{\text{A}}\text{C}(=\text{O})-$ with the N atom linked to the ring A.

19. (Previously Presented) The compound as claimed in claim 17 wherein R^{A} is hydrogen or methyl.

20. (Previously Presented) The compound as claimed in claim 18 wherein s is 1 and Z is hydrogen.

21. (Previously Presented) The compound as claimed in claim 18 or wherein s is 0 and Z is an optionally substituted mono cyclic carbocyclic or heterocyclic ring.

22. (Previously Presented) The compound as claimed in claim 21 wherein Z is optionally substituted phenyl.

23. (Previously Presented) The compound as claimed in claim 1 wherein in the radical R₁ a, b and d are all 0.

24. (Previously Presented) The compound as claimed in claim 1 wherein in the radical R₁ a and d are each 0 and b is 1.

25. (Previously Presented) The compound as claimed in claim 1 wherein in the radical R₁ b is 0 and at least one of a and d is 1.

26. (Previously Presented) The compound as claimed in claim 23 wherein in the radical R₁, B is an optionally substituted monocyclic carbocyclic or heterocyclic ring.

27. (Previously Presented) The compound as claimed in claim 26 wherein B is an optionally substituted cyclopentyl, cyclohexyl, phenyl, 2-,3-, or 4-pyridyl, 2-, or 3-thienyl, 2-, or 3-furanyl, pyrrolyl, pyranlyl, or piperidinyl ring.

28. (Previously Presented) The compound as claimed in claim 27 wherein optional substituents are selected from methyl, ethyl, methoxy, ethoxy, methylenedioxy, ethylenedioxy, methylthio, ethylthio, hydroxy, hydroxymethyl, hydroxyethyl, mercapto, mercaptomethyl, mercaptoethyl, amino, mono- and di-methylamino, monoand di-ethylamino, fluoro, chloro, bromo, cyano, N-morpholino, N-piperidinyl, N-piperazinyl.

29. (Previously Presented) The compound as claimed in claim 1 wherein R₁ is optionally substituted cyclohexyloxy; cyclohexylamino; cyclohexylmethyl, or piperidin-1ylmethyl.

30. (Previously Presented) The compound as claimed in claim 1 wherein R₁ is

4aminocyclohexyloxy; 4-aminocyclohexylamino; 4-hydroxycyclohexylamino, 4aminocyclohexylmethyl, or 4-aminopiperidin-1-ylmethyl.

31. (Previously Presented) The compound as claimed in claim 1 wherein R is hydrogen, chloro, bromo methyl, ethyl, n-propyl, iso-propyl, n-, sec- or tert-butyl, methoxy, methylthio, ethoxy, ethylthio, or a phenyl, benzyl, cyclopropyl, cyclopentyl, cyclohexyl, 2-, 3-, or 4- pyridyl, phenyl, pyridyl, morpholino, piperidinyl, or piperazyl ring.

32. (Previously Presented) The compound as claimed in claim 1 wherein R is chloro, bromo, cyclopentyl, cyclopropyl or isopropyl.

33. (Previously Presented) The compound as claimed in claim 1 wherein in the compound of formula (I) n is 0, ring A is optionally substituted phenyl, Q is dimethylaminosulfonyl, phenylsulfonyl or phenoxy; R¹ is 4-aminocyclohexyloxy, 4aminocyclohexylamino, 4-hydroxycyclohexylamino, 4-aminocyclohexylmethyl, or 4-aminopiperidin-1-ylmethyl, and R is chloro, bromo, cyclopentyl, cyclopropyl or isopropyl.

34. (Previously Presented) A method of treatment of diseases or conditions mediated by excessive or inappropriate kinase activity in mammals comprising administering to the mammal an amount of a compound of formula (I) as defined in claim 1, or a salt, hydrate or solvate thereof, effective to inhibit said kinase activity.


35. (Canceled)

36. (Previously Presented) The method as claimed in claim 34, wherein the kinase activity is CDK2 activity, PDK1 activity, CHK1 activity, or combinations thereof.

37. (Previously Presented) The method of treatment as claimed in claim 34, wherein the kinase activity is associated with cancer, psoriasis or restenosis.

38. (Previously Presented) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a salt, N-oxide, hydrate or solvate thereof, together with a pharmaceutically acceptable carrier.

39. (Previously Presente) A compound of formula (I), or a salt, N-oxide, hydrate or solvate thereof,



wherein n is 0, ring A is optionally substituted phenyl, Q is dimethylaminosulfonyl, phenylsulfonyl or phenoxy, R¹ is 4aminocyclohexyloxy; 4-aminocyclohexylamino; 4-hydroxycyclohexylamino; 4aminocyclohexylmethyl, or 4-aminopiperidin-1-ylmethyl, and R is chloro, bromo, cyclopentyl, cyclopropyl or isopropyl.

40 (Currently Amended) A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 39 together with a pharmaceutically acceptable carrier.